As shown in Figure 5A, PTK2B expression significantly correlates with the general macrophage marker CD68 (R = 0.38, p < 0.001) as well as with the pro‐tumorigenic macrophage marker CD163 (R = 0.34, p < 0.001) in BC patients, and even more profoundly in two independent datasets of TNBC patients (TCGA, n = 138; R = 0.6 (CD68), R = 0.51 (CD163); Figure 5A, GSE76124, n = 198; R = 0.38 (CD68), R = 0.26 (CD163); Figure S5A, Supporting Information). Here, CD163 is linked to breast cancer.